









Mercado
/
Acciones
/
nasdaq-rgen
/

Repligen Corp

RGEN

151.570USD

-9.530-5.92%

Cierre 10/28, 16:00（ET）Cotizaciones retrasadas 15 min

8.53BCap. mercado

PérdidaP/E TTM



Repligen Corp

151.570

-9.530-5.92%

Descripción general Compañía Finanzas Análisis

Descripción general

Compañía

Finanzas

Análisis

Más Datos de Repligen Corp Compañía

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.

Información de Repligen Corp



Símbolo de cotizaciónRGEN

Nombre de la empresaRepligen Corp

Fecha de salida a bolsaApr 29, 1986

Director ejecutivoMr. Olivier Loeillot

Número de empleados1778

Tipo de seguridadOrdinary Share

Fin del año fiscalApr 29

DirecciónBuilding 1, Suite 100

CiudadWALTHAM

Bolsa de valoresNASDAQ Global Select Consolidated

PaísUnited States of America

Código postal02453

Teléfono17814499560

Sitio Webhttps://www.repligen.com/

Símbolo de cotizaciónRGEN

Fecha de salida a bolsaApr 29, 1986

Director ejecutivoMr. Olivier Loeillot

Ejecutivos de Repligen Corp



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Ms. Karen A. Dawes

Lead Independent Director

91.29K

+1.08%

Mr. Glenn P. Muir

Independent Director

32.55K

+3.08%

Mr. Olivier Loeillot

President, Chief Executive Officer, Director

13.06K

-8.72%

Mr. Ralf Kuriyel

Senior Vice President - Research and Development

12.56K

+147.18%

Mr. Nicolas M. Barthelemy

Independent Director

4.94K

+24.53%

Mr. Rohin Mhatre, Ph.D.

Independent Director

3.32K

+41.49%

Dr. Konstantin Konstantinov, Ph.D.

Independent Director

Mr. Jason K. Garland

Chief Financial Officer

Mr. Tony John Hunt

Executive Chairman of the Board

Dr. Martin D. Madaus, Ph.D.

Independent Director

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Ms. Karen A. Dawes

Lead Independent Director

91.29K

+1.08%

Mr. Glenn P. Muir

Independent Director

32.55K

+3.08%

Mr. Olivier Loeillot

President, Chief Executive Officer, Director

13.06K

-8.72%

Mr. Ralf Kuriyel

Senior Vice President - Research and Development

12.56K

+147.18%

Mr. Nicolas M. Barthelemy

Independent Director

4.94K

+24.53%

Mr. Rohin Mhatre, Ph.D.

Independent Director

3.32K

+41.49%

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de oct

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

Sin datos

Por regiónUSD

Nombre

Ganancia

Proporción

North America

89.36M

49.00%

Europe

69.30M

38.00%

APAC/Other

23.71M

13.00%

Por negocio

Por región

Sin datos

Estadísticas de accionistas

Actualizado: sáb., 16 de ago

Accionistas

Tipos de accionistas

Accionistas

Proporción

The Vanguard Group, Inc.

9.00%

BlackRock Institutional Trust Company, N.A.

8.37%

T. Rowe Price Associates, Inc.

6.10%

Roy T. Eddleman UEO

5.89%

Point72 Asset Management, L.P.

3.40%

Otro

67.25%

Accionistas

Proporción

The Vanguard Group, Inc.

9.00%

BlackRock Institutional Trust Company, N.A.

8.37%

T. Rowe Price Associates, Inc.

6.10%

Roy T. Eddleman UEO

5.89%

Point72 Asset Management, L.P.

3.40%

Otro

67.25%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

54.39%

Investment Advisor/Hedge Fund

25.75%

Hedge Fund

12.98%

Individual Investor

6.38%

Research Firm

2.41%

Pension Fund

2.37%

Bank and Trust

0.68%

Sovereign Wealth Fund

0.60%

Family Office

0.50%

Participación institucional



Actualizado: mié., 1 de oct

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q3

1008

55.75M

99.10%

-5.55M

2025Q2

1028

61.98M

110.32%

-3.21M

2025Q1

1054

62.91M

111.98%

-2.72M

2024Q4

1054

61.13M

109.11%

-3.76M

2024Q3

1046

60.75M

108.48%

-6.10M

2024Q2

1039

61.28M

109.67%

-2.73M

2024Q1

1036

60.56M

108.45%

-5.41M

2023Q4

1062

62.13M

111.29%

-2.30M

2023Q3

1063

61.47M

110.27%

+2.91M

2023Q2

1050

59.01M

105.99%

+1.34M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

The Vanguard Group, Inc.

5.07M

-2.87K

-0.06%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

4.71M

8.37%

-180.36K

-3.69%

Jun 30, 2025

T. Rowe Price Associates, Inc.

3.43M

6.1%

-3.13M

-47.69%

Aug 31, 2025

Roy T. Eddleman UEO

3.31M

5.89%

-67.50K

-2.00%

Dec 31, 2024

Point72 Asset Management, L.P.

1.91M

3.4%

+796.75K

+71.36%

Jun 30, 2025

State Street Investment Management (US)

1.62M

2.88%

-66.31K

-3.93%

Jun 30, 2025

Champlain Investment Partners, LLC

1.40M

2.49%

-62.91K

-4.30%

Jun 30, 2025

Fidelity Management & Research Company LLC

1.36M

2.43%

+842.96K

+161.67%

Jun 30, 2025

Sands Capital Management, LLC

1.25M

2.22%

-43.11K

-3.33%

Jun 30, 2025

Invesco Advisers, Inc.

1.25M

2.22%

-348.59K

-21.85%

Jun 30, 2025

ETFs relacionados



Actualizado: lun., 6 de oct

Nombre

Proporción

First Trust NYSE Arca Biotechnology Index Fund

3.05%

Invesco Biotechnology & Genome ETF

2.57%

Congress SMid Growth ETF

1.97%

iShares Health Innovation Active ETF

1.52%

VanEck Biotech ETF

1.27%

Franklin Genomic Advancements ETF

0.98%

WisdomTree BioRevolution Fund

0.98%

Pacer US Export Leaders ETF

0.87%

iShares Biotechnology ETF

0.63%

First Trust Multi-Manager Small Cap Opportunities ETF

0.5%

First Trust NYSE Arca Biotechnology Index Fund

Proporción3.05%

Invesco Biotechnology & Genome ETF

Proporción2.57%

Congress SMid Growth ETF

Proporción1.97%

iShares Health Innovation Active ETF

Proporción1.52%

VanEck Biotech ETF

Proporción1.27%

Franklin Genomic Advancements ETF

Proporción0.98%

WisdomTree BioRevolution Fund

Proporción0.98%

Pacer US Export Leaders ETF

Proporción0.87%

iShares Biotechnology ETF

Proporción0.63%

First Trust Multi-Manager Small Cap Opportunities ETF

Proporción0.5%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos

KeyAI

